Tissue fibrosis results when dysregulation of extracellular matrix (ECM) turnover favors deposition of collagen and other ECM proteins over degradation. Fibrosis may then lead to organ dysfunction and pathology as observed in systemic sclerosis (SSc). In the present study, we investigated the antifibrotic properties of proteasome blockade. A dose-and time-dependent reduction in type-I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) production was observed in normal fibroblasts exposed to proteasome inhibitors (PI). In the same culture conditions, metalloproteinase-1 (MMP-1) protein and the collagenolytic activity on type I collagen was increased. The steady-state mRNA levels of COL1A1, TIMP-1, and MMP-1 paralleled protein levels. These effects were dominant over the profibrotic properties of TGF-β and were observed with fibroblasts generated from normal and SSc skin. PI decreased type I collagen mRNA levels with kinetics similar to those observed with DRB, a specific RNA polymerase II inhibitor, thus indicating transcriptional inhibition. Of interest, PI induced c-Jun phosphorylation and c-Jun nuclear accumulation. The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose-dependent fashion, the up-regulated synthesis of MMP-1 induced by PI. Finally, PI did not affect fibroblast viability. Thus, the coordinated down-regulation of collagen and TIMP-1 and up-regulation of MMP-1 renders proteasome blockade an attractive strategy for treating conditions as SSc, characterized by excessive fibrosis.
subsequently undergoes maturation. The transcription of COL1A1 and COL1A2 collagen genes is regulated by elements with repressor and enhancer functions that are differently recruited under basal and inflammatory conditions (3) (4) (5) .
Metalloproteinases (MMP) participate in ECM degradation. Their production is transcriptionally regulated and require stepwise activation from inactive precursors (proMMP) (6) . Their activity depends further on interactions with extracellular matrix components and binding to endogenous inhibitors such as tissue inhibitor of metalloproteinases (TIMP) (7) . MMP-1, or interstitial collagenase, has the distinctive capacity (shared with MMP-8, MMP-13, and MMP-14) to cleave the triple helix of type I collagen, allowing the chains to unwind and become susceptible to further degradation (8) .
Considered a master cytokine leading to fibrosis, transforming growth factor-β1 (TGF-β) upregulates type I collagen and TIMP-1, while down-regulating MMP-1 gene transcription (9) (10) (11) (12) . In contrast, the proinflammatory cytokine TNF-α exerts antifibrotic activities by reducing the expression of ECM genes, suppressing TGF-β collagen induction, and inducing MMP production (13) . TNF-α cell signaling involves principally NF-κB and the MAP kinase cascade. Recent data have shown that of the MAP kinases, p38 and ERK favor ECM deposition, whereas JNK is generally considered to be antifibrotic (14) . Activated protein-1 (AP-1) consists of homoand hetero-dimers of the Jun (c-Jun, JunB, JunD) and Fos family (c-Fos, FosB, Fra1, Fra2). It acts as transcription factor and its complementary regions are present on the 5′-flanking regions of MMP-1 and TIMP-1, and on the first intron of COL1A1 (15) (16) (17) (18) (19) (20) . AP-1 may increase the levels of MMP-1 and decrease those of collagen (21) (22) (23) .
Systemic sclerosis (SSc) or scleroderma is a disease of unknown origin, characterized by fibrosis of the skin and internal organs associated with diffuse fibroproliferative microangiopathy and the presence of autoantibodies (24) . Fibroblast hyperactivation with increased collagen synthesis is a hallmark of SSc and is accompanied by an inflammatory infiltrate with abundant T cells (25, 26) , which profoundly affect collagen synthesis in a contact-dependent manner (27, 28) .
One of the activities of the proteasome, a barreled structure consisting of several subunits having multicatalytic proteinase enzymatic properties, is to degrade proteins involved in transcription regulation, such as NF-κB (29) . Proteasome inhibitors (PI) have been developed and are being tested in clinical trials with the aim of reducing inflammation (30) or tumor growth. The PI bortezomid has recently been approved for treatment of refractory multiple myeloma (31) .
In the present study, we have investigated the effect of proteasome blockade on the capacity of human dermal fibroblasts to renew and degrade ECM. To this end, the production of type I collagen, MMP-1, and TIMP-1 was evaluated under resting and stimulated conditions in the presence of proteasome inhibitors. Our findings indicate that proteasome blockade profoundly alters fibroblast metabolism favoring degradation over production of ECM components.
MATERIALS AND METHODS

Patients and controls
Six patients with early active diffuse cutaneous SSc and 5 controls matched for age and gender were recruited at the Department of Rheumatology, University Hospital, Lund, Sweden. They all fulfilled the American College of Rheumatology criteria for the classification of SSc. None of them was receiving immunosuppressant agents. This study was approved by the ethical committee of the institutions involved. Written informed consent was obtained from patients and healthy individuals. Lesional skin was excised from the forearm under local anesthesia. Further characteristics of patients have been described (27) .
Reagents
Dulbecco's modified Eagle's medium (DMEM), nonessential amino acids, sodium pyruvate, penicillin, and streptomycin were from Gibco (Invitrogen); MG-132 (Z-Leu-Leu-Leu-CHO), synthetic lactacystin, proteasome inhibitor I (PSI) [Z-lle-Glu(OtBu)-Ala-Leu-CHO], SN50 cellpermeable inhibitor peptide, SP 600125 (JNK Inhibitor II), sodium orthovanadate from Calbiochem (Darmstadt, Germany); 5,6-dichlorobenzimidazole riboside (DRB), 7-aminoactinomycin (7-AAD), α-ketoglutaric acid, β-amino propionitrile, and fetal calf serum (FCS) from Sigma (St. Louis, MO); bortezomib (Velcade) from Millennium Pharmaceuticals (Cambridge, MA); human recombinant TGF-β from R&D Systems (Minneapolis, MN); complete protease inhibitor cocktail from Roche (Mannheim, Germany). Vehicle for PSI, MG-132, and lactacystin was DMSO, and water for bortezomid. Maximal vehicle concentration was 4 μl/ml.
Culture conditions
Human skin fibroblasts were generated from skin biopsies, cultured as described (27) , and used from passage 4 to 9.
Type I collagen, MMP-1 and TIMP-1 protein production assay
For protein production, fibroblasts were cultured in 96-well plates at 2×10 4 cell/well in 200 µl in DMEM supplemented with 1% FCS, 25 μg/ml L-ascorbic acid, 3.4 μg/ml α -ketoglutaric acid, and 50 μg/ml β-amino propionitrile in order to favor normal collagen fibrillogenesis (32) . In experiments in which total collagen production was assessed, culture medium was without serum, α-ketoglutaric acid, and β-amino propionitrile. Proteasome inhibitors (PSI or bortezomib or lactacystin or MG-132 at concentrations from 20 μM to 0.0048 μM), or TGF-β (10 ng/ml), or TGF-β and PSI, or medium alone, were added for 48 or 72 h. The supernatants were then stored at -20°C until protein determination. All experimental conditions were tested in triplicate. The ELISA for human tissue inhibitor of metalloproteinases 1 (TIMP-1) (R&D), and for promatrix metalloproteinase I (pro-MMP-1) (Binding Site, Birmingham, UK), and the RIA for the determination of N-terminal propeptide of type I procollagen (PINP-1) (Orion Diagnostica, Espoo, Finland) were performed following the manufacturer's instructions. Syrcol soluble collagen assay (Biocolor Ltd., New Townabbey, Northern Ireland) was used to quantify total collagen.
Collagenase assay
Collagenase activity was assessed by ELISA on type I calf skin collagen (Sigma, St Louis, MO) coated for 7 days onto 96-well plates, as described previously (33) . Samples were activated with trypsin 100 μg/ml for 20' at 37°C, to convert latent collagenase into its active form), followed by a fivefold excess addition of Soybean trypsin inhibitor (Worthington, Freehold, NJ), and tested in triplicate. The undigested collagen was detected with an anti-type I collagen mouse monoclonal antibody (Calbiocherm, La Jolla, CA) followed by alkaline phosphatase-labeled anti mouse IgG sheep antibody (Cappel, West Chester, PA). One unit of collagenase was defined as the activity that solubilizes 1 μg of native collagen in 1 min.
Western blot analysis
Fibroblasts were cultured in serum-free conditions. Fibroblast protein was extracted in lysis buffer containing protease and phosphatase inhibitors. Twenty micrograms of total protein extracts were separated by 10% SDS-PAGE under reducing conditions and electroblotted onto nitrocellulose membrane (Hybond TM ECL TM Amersham Pharmacia, Piscataway, NJ). Blots were incubated with antibodies to IκB-α, phospho-IκB-α (ser 32), c-Jun, phospho-c-Jun (ser 73), phospho p44/42 MAPK (Thr 202/Tyr 204), phospho-p38 MAPK (Thr 180, Tyr 182) (Cell Signaling, Beverly, MA), and β-tubulin (Sigma, St. Louis, MO), and revealed by HRPconjugated anti-rabbit or anti-mouse IgG (DAKO Cytomation, Giostrup, Denmark). The bound proteins were detected by chemiluminescence using ECL system (Amersham Pharmacia Biotech). The intensity of the bands was quantified by densitometric analysis.
Indirect immunofluorescence
Dermal fibroblasts were grown on glass coverslips, serum-starved overnight, and cultured in serum-free conditions in the presence of medium, or TNF-α, or MG-132 10 μM for various periods of time. Cells were then fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized in 0.1% saponin, 1% BSA in PBS for 30 min, and subsequently incubated with anti-NF-κB p65 (Santa Cruz, CA) or anti-c-Jun Ab for 1 h, followed by Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes, Eugene, OR). Images were acquired using a Zeiss Axiophot fluorescence microscope equipped with Axiocam Color CCD Camera, at 360-fold magnification. Images were taken using a fixed setting of 1500 ms, and fluorescence intensity was quantified by MetaMorph software (Molecular Devices Corporation, Sunnyvale, CA) The intensity of total nuclear fluorescence was measured and normalized for the nuclear area.
Determination of mRNA levels of COL1A1, MMP-1, and TIMP-1 Confluent fibroblasts were serum-starved overnight. PI (from 40 to 0.04 µM), medium alone, or TGF β (10 ng/ml), was then added to serum-free DMEM and cultured for further 24 h, unless stated otherwise. In mRNA transcription experiments, DRB (50 μM) was added alone or 3 h after PI, and cultures were stopped after 3, 6, 12, and 24 h. Total RNA was isolated by RNeasy Mini Kit (Qiagen, Valencia, CA). Samples were homogenized on QIA shredder columns (Qiagen) before RNA isolation, and treated with Rnase-Free Dnase set (Qiagen) to remove DNA during RNA purification. The quality of RNA, checked by the Agilent Technologies 2100 Bioanalyzer (ver. A02.12 SI 292) to estimate the rRNA ratio (28S/18 s), ranged between 1.8 and 2.2 in all the experiments. human MMP-1, TIMP-1, COLA1A, GADPH, and 18S rRNA, were purchased from Applied Biosystems (Foster City, CA). The primers and probes for human eukaryotic translation elongation factor 1 α 1 (EEF1A1) (forward, 5′-AGCAAAAATGACCCACCAATG-3′ and reverse,5′-GGCCTGGATGGTTCAGGATA-3′), and human transferrin receptor (TFRC) (forward, 5′ CATTTGTGAGGGATCTGAACCA-3′ and reverse, 5′-CGAGCAGAATACAGCCACTGTAA-3′) were provided by Genomic Platform, NCCR Frontiers in Genetics, University of Geneva. The GeNorm program was used to select the two best housekeeping genes among GAPDH, 18S, EEF1A1, TFRC, and TBC, based on stability in response to experimental treatments (34) . The results were normalized to the geometric mean of two housekeeping genes (EEF1A1 and TFRC) except for experiments involving DRB, which directly affected the levels of these genes that were substituted by 18S. PCR was performed in triplicate using ABI PRISM 7900 Sequence Detection System (Applied Biosystems) in a final volume of 10 μl. The thermal cycler conditions were the following: 50°C for 2 min, 95°C for 10 min, then 50 cycles of 95°C for 15 s and 60°C for 1 min. cDNA synthesis without RNA or cDNA synthesis without reverse transcriptase used as controls were negative for amplification products.
Northern blot analysis
Ten micrograms of total RNA was resolved on MOPS formaldehyde 1% agarose gel and transferred to Hybond-N nylon membrane (Amersham, Little Chalfont, UK). The membrane was hybridized with 32 P-dCTP labeled c-DNA probes specific for human procollagen α1(I), MMP-1, TIMP-1, and GAPDH (kind gift from Dr. H. G. Welgus. St. Louis, MO) (23) . Signal intensity was determined by phosphoimaging (Typhoon 9400), and analyzed using ImageQuant Software 5.2 (Molecular Dynamics). All membranes were subjected to autoradiography using Kodak Biomax autoradiography films (Eastman Kodak Company, Rochester, NY).
Fibroblasts viability assay
Fibroblasts seeded at 5×10 3 cells/well into 96-well plates were cultured in serum-free DMEM for various periods of times in the presence of PSI or bortezomib with or without SP-600125. Fibroblast proliferation was then assessed using the EZ4U reagent (Biomedica, Vienna, Austria) and by flow cytometric analysis by 7-aminoactinomycin D (7-AAD) staining (35) .
Statistical analysis
The IC 50 of PSI on the production of type I collagen, MMP-1, and TIMP-1 by dermal fibroblasts was computed by linear regression analysis upon plotting the protein concentration over the logarithmic value of the PSI concentration used. Student's t test was used to analyze differences between two groups. One-way ANOVA test (Dunnett method) was used to assess the differences among groups. A P value ≤ 0.05 was considered statistically significant.
RESULTS
Proteasome inhibitors reduce type I collagen and TIMP-1, while increasing MMP-1 protein production in dermal fibroblasts
Because proteasome controls gene expression and protein production by degrading ubiquitintagged proteins, including transcription factors, we tested whether blockade of proteasome would affect the production of proteins involved in ECM synthesis and degradation. Type I collagen production was strongly and dose-dependently reduced in normal dermal fibroblasts incubated with PSI, a peptide aldehyde that causes reversible inhibition of the multicatalytic proteinase proteasome complex (Fig. 1A) . At high PSI concentrations (micromolar range), the constitutive production of type I collagen was consistently inhibited by more than 80%, while at nanomolar concentration PSI still had some inhibitory activity (Fig. 1A) . Interestingly, in the same culture conditions PSI induced a dose-dependent increase of MMP-1, of approximately fivefold at micromolar concentration (Fig. 1B) . Furthermore, addition of PSI led to decreased TIMP-1 levels, again in a dose-dependent manner (Fig. 1C) . Thus, by reducing type I collagen and TIMP-1, while increasing MMP-1 protein production, PSI has the capacity of substantially modifying the production by fibroblasts of proteins involved in ECM turnover. We then tested whether PSI activity was unique or whether other proteasome inhibitors would have a similar effect on fibroblast protein production. MG-132, a peptide aldehyde reversible inhibitor, synthetic lactacystin, an irreversible proteasome inhibitor, and bortezomib, a peptide boronate reversible inhibitor, were all able to reduce type I collagen and TIMP-1 and increase MMP-1 production in a dose-dependent manner (Fig. 1D-L) . Thus, proteasome blockade, regardless of the inhibitor used, decreases the production of type I collagen and TIMP-1 and up-regulates that of MMP-1. However, the relative potency of these compounds differed: 0.01 μM bortezomib sufficed to reduce collagen production by 50%; PSI and MG-132 achieved similar levels of collagen reduction at a concentration higher by one order of magnitude (0.1-0.2 μM); while lactacystin at the highest concentration tested (20 μM) did not even reach 50% of inhibition. Similarly, higher concentrations of lactacystin were needed to enhance MMP-1 or reduce TIMP-1 when compared with bortezomib, PSI and MG-132.
Proteasome inhibitors reduce COL1A1 and TIMP-1, and increase steady-state mRNA levels of MMP-1 in dermal fibroblasts
To determine whether the changes observed at the protein level were matched by changes at the mRNA level, we tested by quantitative real time RT-PCR and Northern blot whether proteasome blockade would result in changes of COL1A1, MMP-1, and TIMP-1 mRNA steady-state levels. In fibroblasts cultured for 24 h PSI, MG-132, and lactacystin reduced COL1A1 steady-state mRNA levels by 87%, 96%, and 20% of control cultures, respectively ( Fig. 2A) . In the same experimental conditions, MMP-1 mRNA levels increased by 370%, 820%, and 160%, while TIMP-1 mRNA levels were 80%, 50%, and 60% of controls ( Fig. 2A) . These effects were dosedependent (Fig. 2B) . In fibroblasts treated with PSI, the steady-state levels of COL1A1 and TIMP-1 mRNA changed with time and significant differences compared with control cultures were observed at 6 h, to become maximal at 24 h (Fig. 2C) . Similar results were obtained by Northern blot analysis (Fig. 2D, E) . Of interest, MMP-1 mRNA levels decreased as a function of time in the absence of PI, while they did not in the presence of PSI. Thus the increased MMP-1 mRNA levels observed after 24 h of culture ( Fig. 2A, B) reflected a decreased reduction in mRNA levels when fibroblasts were cultured in the presence of PSI.
We then tested whether the decreased levels of COL1A1 mRNA were due to changes in mRNA transcription rate or mRNA stability. For these experiments, fibroblasts were treated with the transcription inhibitor DRB in the presence or absence of PSI (4 μM), and the decay of COL1A1 mRNA was monitored as function of time by quantitative RT-PCR. The half-life of COL1A1 mRNA in the presence of DRB was ~11 h, and it was the same when DRB and PSI were used together (Fig. 3) . These results strongly indicate that the effect of PSI-induced proteasome blockade on type I collagen synthesis was essentially due to decreased synthesis rather than stability of mRNA. The decay of COL1A1 mRNA in the presence of PSI alone also followed similar kinetics (Fig. 3) . Similar results were observed in three additional experiments, one of which was performed in the presence of MG-132 (not shown). Because 18S RNA levels were constant over time in all culture conditions, a toxic effect of DRB used in conjunction with PI was ruled out (data not shown). Of interest, the expression level of COL1A1 mRNA in untreated control cultures did not substantially change with time, thus indirectly indicating that under our culture conditions fibroblasts maintain active COL1A1 mRNA synthesis (Fig. 3) .
Overall, these data indicate that proteasome blockade, by reducing COL1A1 and TIMP-1 and increasing MMP-1 mRNA levels with parallel changes at the protein level, profoundly affects the transcription of genes coding for proteins involved in ECM deposition and turnover.
Effect of PSI in normal and SSc skin fibroblasts
It has been reported that the phenotype of SSc fibroblasts as compared with controls is altered, which characteristic persists in vitro for multiple cellular generations. We therefore tested whether proteasome blockade by PSI would also reduce type I collagen and TIMP-1 and enhance MMP-1 in SSc fibroblasts. The effect of various doses of PSI was assessed simultaneously on 6 SSc and 5 control fibroblast lines. The doses of PSI necessary to reduce 50% of type I collagen protein levels did not significantly differ between SSc and control fibroblasts (Fig. 4, Table 1 ), but the doses required to enhance MMP-1 production by 50% tended to be higher in SSc than in control fibroblasts (P=0.066, Fig. 4 , Table 1 ). Of note, significantly higher doses of PSI were required to inhibit type I collagen than to enhance the production of MMP-1 both in control and SSc fibroblasts (P=0.01, Table 1 ). PSI reduced TIMP-1 levels by more than 50% in 3 of 5 normal fibroblasts but in all 6 SSc fibroblasts, and the doses of PSI required to reduce TIMP-1 production by 50% were higher than those needed to reduce collagen production (Table 1) . Thus, proteasome blockade is as effective in SSc as in control fibroblasts. Furthermore, the amount of PSI required to inhibit TIMP-1 is higher than that required to inhibit type I collagen, this being higher than that required to enhance MMP-1 production.
Proteasome blockade inhibits the profibrotic activity of TGF-β
In vitro TGF-β coordinately enhances type I collagen and TIMP-1, while decreasing MMP-1 production and in vivo is thought to contribute to fibrogenesis (9) . We were therefore interested in assessing the effect of proteasome blockade on fibroblasts cultured in the presence of TGF-β. Type I collagen protein production doubled in the presence of TGF-β compared with medium. When PSI was added to TGF-β-stimulated fibroblasts, we observed a significant fivefold reduction in type I collagen levels, well below the levels of spontaneous production (Fig. 5A) . TGF-β did not modify baseline MMP-1 levels. PSI doubled the amount of MMP-1 produced in the presence of TGF-β, which enhancement was lower than the one observed in the absence of TGF-β (Fig. 5A) . Finally, TIMP-1 production was increased threefold in the presence of TGF-β, which effect was abrogated by PSI (Fig. 5A) . The results were similar when steady-state mRNA levels were assessed by quantitative RT-PCR (Fig. 5B) . Because the assay used to assess type I collagen production was based on the specific recognition of the N terminus peptide, we seek to extend our findings to all soluble collagens produced by dermal fibroblasts. To this end, we used a Sirius red-based assay to detect total collagen in cultures performed in the absence of serum. Consistent with our previous findings, PI strongly reduced total collagen in 48 h and 72 h culture supernatants in unstimulated and stimulated (TGF-β) conditions (Fig. 5C) . Thus, our data indicate that proteasome blockade effectively abolishes the profibrotic activity of TGF-β. Moreover, in the same culture conditions, PI strongly enhanced in a time-dependent manner the collagenolytic activity detectable in supernatants of fibroblasts, whether in the absence or presence of TGF-β. Indeed, by 72 h, the capacity to digest type I collagen was 10 times higher in the presence than in the absence of PI (Fig. 5D ).
Proteasome blockade results in c-Jun phosphorylation and c-Jun nuclear accumulation
Proteasome blockade is known to inhibit IκB-α degradation and therefore to block NF-κB nuclear translocation. In addition, it may affect the levels of many other transcription factors. To unravel, at least in part, the mechanisms involved in the phenomena that we observed, we tested whether PI could affect the levels of various MAP kinases. Whereas TNF-α, used as positive control, induced prompt phosphorylation of c-Jun, ERK, p38, and IkB-α (accompanied by IkBα degradation) according to Western blotting (Fig. 6A) , MG-132 10 μM specifically induced in a time-dependent manner c-Jun phosphorylation and c-Jun accumulation that peaked at 12 h (Fig.  6A) . Consistent with these findings, fluorescence intensity of nuclear c-Jun was considerably increased in a time-dependent manner upon PI treatment, but unstimulated NF-κB levels were not affected (Fig. 6B) . In control cultures, PI suppressed as expected NF-κB nuclear translocation induced by TNF-α (Fig. 6B) . To ascertain whether the PI effect on c-Jun accumulation was due to c-Jun phosphorylation, we used the specific pharmacological inhibitor of the c-Jun N-terminal kinase SP-600125 and, indeed, inhibition of JNK abrogated c-Jun accumulation (Fig. 6C) . Thus, in dermal fibroblasts, proteasome inhibition induces c-Jun accumulation in the nucleus, an event favored by enhanced JNK activity.
Inhibition of JNK abrogates the enhanced MMP-1 production induced by PI
The promoter region of the MMP-1 gene is known to possess an AP-1 binding site (15) (16) (17) . Because c-Jun is a member of the proteins forming AP-1, we tested whether inhibition of JNK would reverse the enhanced MMP-1 production induced by PI. In fibroblasts cultured in the presence of bortezomib (0.1 μM), the addition of the JNK inhibitor SP-600125 reduced in a dose-dependent manner the production of MMP-1 (Fig. 6D) . No substantial modifications in the levels of type I collagen or TIMP-1 were observed in the same culture conditions (not shown), thus indicating that the enhanced production of MMP-1 induced by PI is due to mechanisms distinct from those involved in collagen and TIMP-1 reduction. In parallel control experiments, we tested whether the inhibition of NF-κB nuclear translocation by SN50 cell-permeable inhibitor peptide would reverse the enhanced MMP-1 production induced by PI. No such effect was found; on the contrary a twofold increase was observed at high inhibitor concentrations (Fig. 6D) . These data are consistent with the results obtained by Western blot analysis, indicating that PI do not induce significant modification in the levels of IκB-α nor IκB-α phosphorylation under basal conditions (Fig. 6A) , and further stress the specificity of the effect of PI on c-Jun.
Effect of PI on fibroblast viability
Because proteasome blockade may result in apoptotic death of treated cells (36), we tested whether in our culture conditions a decrease in fibroblast viability could account, at least in part, for the results. Compared with fibroblasts cultured for up to 72 h in medium alone, cells exposed to increasing doses of PSI did not show impaired growth except at very high concentration (40 μM), and only after 72 h of culture (Fig. 7A) . Similar results were obtained in the presence of bortezomid at concentrations up to 1.25 µM. In addition, the viability of fibroblasts cultured for 48 h in the presence of bortezomib (0.1 μM) and JNK inhibitor SP-600125 (20 μM) was 85.1% ± 5.9 of that of fibroblasts cultured in medium alone. These results were also confirmed when the proportion of apoptotic/necrotic cells was examined by 7-AAD staining (35) . No significant differences were observed between fibroblasts cultured for 48 h in the absence or presence of increasing amounts of PSI (Fig. 7B ). In conclusion, dermal fibroblast viability was not substantially affected by PI in our culture conditions.
DISCUSSION
The treatment of fibrotic conditions, particularly in the case of systemic sclerosis, remains a challenge, as no current therapeutic option has been definitively validated by controlled clinical studies. This highlights the need for new therapeutic tools. In this study conducted in vitro with human dermal fibroblasts, we provide for the first time evidence that proteasome blockade may be considered a novel strategy for controlling fibrotic diseases. Indeed, in dermal fibroblasts proteasome blockade resulted in a marked modification of gene expression leading to the reduction of ECM synthesis and increase of ECM degradation, due to the down-regulation of type I collagen and TIMP-1 and the up-regulation of MMP-1 protein production and collagenolytic activity. Of additional interest, proteasome blockade resulted in similar modifications when fibroblasts were under resting conditions in cultures without serum or when activated by TGF-β. In addition, SSc fibroblasts-whose gene expression is known to be dysregulated and profibrotic-showed a similar response to proteasome blockade.
As far as collagen is concerned, our data are in agreement with recent evidence obtained on rat cardiac fibroblasts, in which proteasome blockade resulted in the reduced expression of COL1A1, COL1A2, and COL3A1 mRNA. This reduction was associated with reduced myocardial fibrosis in a rat model of hypertension (37) . When we examined the mechanisms involved in the decreased production of type I collagen protein, we demonstrated that this was exclusively due to reduced transcriptional activity. Indeed, when proteasome was blocked by PI, COL1A1 mRNA levels decreased with kinetics identical to those measured in the presence of the transcription inhibitor DRB (Fig. 3) . Regulation of COL1A1 gene transcription is highly complex and involves enhancing and inhibitory elements. Transcription factors with activating properties are differently involved under resting conditions in which SP-1 may play a major role (38) , and in TGF-β-stimulated conditions where not only SP-1, but also Smad3/4 directly or through AP-1 in conjunction with the transcriptional coactivator p300 are known to be important (39, 40) . In addition, it is known that PI has the potential to modify the availability of Smads with activator and inhibitory functions, therefore altering the levels of proteins involved in TGF-β signal transduction (41) . Additional contribution of MAP kinases may be at play in TGF-β stimulated cells (14) . In contrast, NF-κB, B-Myb, Fli-1, and p53, among others, may inhibit COL1A1 gene transcription (3) . Some of these factors such as NF-κB, AP-1, SP-1, and p53 are known to be degraded by proteasome (29) . Which of them is (are) involved in the inhibition of collagen gene transcription by proteasome blockade remains to be determined.
Metalloproteinases are induced in many cell types by proinflammatory cytokines such as IL-1 and TNF-α (42) . Recent reports indicate that proteasome inhibition results in decreased levels of MMP-1 and MMP-3 in TNF-stimulated human chondrocytes (43) , and decreased levels of MMP-2 and MMP-9 in both resting and IL-1-stimulated rat fibroblasts (37) . In agreement with Page 9 of 23 (page number not for citation purposes) these findings, proteasome blockade resulted in dose-dependent reduction of MMP-1 production when dermal fibroblasts were activated by T cell contact (Fineschi and Chizzolini, unpublished results). Contrary to these observations, we now report that in resting and TGF-β-stimulated fibroblasts proteasome blockade led to increased levels of MMP-1 protein and collagenase activity. Similarly, proteasome inhibition has been reported to induce an increase in mRNA levels of stromelysin (MMP-3) in rat mesangial cells (44) . Interestingly, in the presence of PI compared with medium, MMP-1 protein and mRNA levels increased. This indirectly indicates that PI inhibition favors stabilization of MMP-1 mRNA or active transcription of MMP-1 gene. However, because the increased levels of MMP-1 protein and collagenolytic activity induced by PI greatly exceeded the relative increase in MMP-1 mRNA levels, translational mechanisms, including stabilization of pro-MMP-1 protein, could also be at play. In this regard, among enzymes known to be involved in pro-MMP-1 activation, MMP-2 and MMP-9 are decreased while MMP-3 is increased upon PI in cells under resting conditions (37, 44) . Ets-1, c-Jun, p38 MAPK, and NF-κB transcription factors, all of which regulated by proteasome activity, are known to act on various MMP-1 promoter regions, and p38 MAPK was shown to enhance MMP-1 mRNA stabilization (45) . Our data point to a role for c-Jun in the enhanced production of MMP-1 in dermal fibroblasts cultured in the presence of PI. On the one hand, PI induced a time-dependent c-Jun phosphorylation and c-Jun accumulation. On the other hand, pharmacological inhibition of JNK resulted in the reversal of c-Jun phosphorylation and c-Jun accumulation induced by PI and, in addition, reduced dose-dependently the enhanced production of MMP-1. Such effects were specific insofar as 1) we did not detect significant modifications induced by PI in the phosphorylation and protein levels of other MAP kinases of IκB-α and NF-κB; 2) the inhibition of nuclear translocation of NF-κB by SN-50 did not reverse the effect of PI; and 3) JNK inhibition did not reverse the effect of PI on collagen and TIMP-1 reduction. These findings are consistent with previous data indicating that PI results in 1) c-Jun or AP-1 accumulation in rat fibroblasts and mesangial cells, as well as in human endothelial cells (44, 46, 47) ; 2) the presence of AP-1 binding sites on the 5′-flanking region of MMP-1 gene (15) (16) (17) , and 3) the capacity of AP-1 to increase MMP-1 production (21). Because by inhibiting JNK, we reversed the effect of PI on MMP-1 but not on COL1A1 and TIMP-1, it is difficult to ascribe all the phenomena observed to the effect of PI on c-Jun. It is, however, very likely that the transcriptional pathways involved would be connected with each other.
Although in our experiments PI did reduce TIMP-1 production, the doses of inhibitors required were higher than those for reducing type I collagen. Possible explanations could be the longer TIMP-1 mRNA half-life (in preliminary experiments it was of ~33 h) compared with COL1A1 mRNA (~11 h) and the importance of translational mechanisms involved in TIMP-1 accumulation (7, 20) . Nonetheless, by reducing TIMP-1 production in resting and TGF-β-activated fibroblasts, PI further favors a collagenolytic phenotype in fibroblasts.
Despite the expected differences in potency of the four PI used (bortezomib > MG-132 ≈ PSI > lactacystin), their effects on type I collagen, MMP-1, and TIMP-1 production by dermal fibroblasts were similar. This strongly suggests that the observed phenomena were due to specific proteasome blockade rather than to other mechanisms. Furthermore, although at a very high concentration (40 μM), PSI decreased fibroblast viability after 3 days of culture, the IC 50 for type I collagen (0.36±0.22 μM), MMP-1 (0.10±0.05 μM) and TIMP-1 (1.14±1.00 μM) was well below this dose. In addition, the increased production of MMP-1 that matched increasing doses of PI argues against a toxic-related effect to explain type I collagen and TIMP-1 reduction. Although PI are considered promising drugs for cancer therapy because of their proapoptotic effects, there is no general agreement on their ability to induce apoptosis in every condition. Indeed, two recent studies have demonstrated an antiapoptotic effect of PI via inhibition of JNK (48) or increase of Mcl-1, an antiapoptotic protein of the bcl-2 family (49). Thus, the final pro-or anti-apoptotic effect will depend on the balance between different transcription factors regulated by PI and cell type.
In conclusion, our in vitro study on human dermal fibroblasts demonstrating that PI are capable of reducing type-I collagen and TIMP-1 and of inducing MMP-1 production provides further support and better understanding of their antifibrotic activity observed by others in vivo in models of fibrosis (37, 50) . Therefore, proteasome blockade could be considered a useful strategy for the treatment of diseases characterized by excessive ECM deposition, as in the case of SSc. Fibroblast cell lines generated from five normal and six SSc individuals (all at passage 4) were cultured for 48 h in the presence of increasing amounts of PSI. Conditions as described in the legend of Fig. 1 . Results of collagen and TIMP-1 protein determinations were expressed as percentage of the medium value (100%), while MMP-1 protein determination as a percentage of maximal response obtained at 2.5 µM. 100% collagen = 231.3 ± 129 ng/ml (controls), 251.3 ± 53 ng/ml (SSc). 100% TIMP-1 = 109.3 ± 34 ng/ml (controls), 142.9 ± 59 ng/ml (SSc). 100% MMP-1 = 3902.1 ± 2386 ng/ml (controls), 7135.3 ± 3937 ng/ml (SSc). Data presented are the mean ± SD of triplicates of one of three independent experiments. B) 7-AAD FACS analysis. Cells were heated at 56°C for 10' in order to induce necrosis. Cell death percentage was 6.37% in panel B1, 8 .28% in B2, and 27.17% in B3.
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